Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Data on Novo Nordisk experimental weight loss drug show mostly mild side effects Reuters TrimRX Novo Nordisk submits application for FDA approval of CagriSema for weight management Novo Nordisk's Bold 3% Gain After Cagrilintide Data Novo Nordisk shares higher on positive Phase 3 trial results for obesity drug Cagrilintide NYSE:NVO